trending Market Intelligence /marketintelligence/en/news-insights/trending/ArYfpYSzsVkTUfz6_tk7UQ2 content esgSubNav
In This List

Congo approves Merck vaccine in face of Ebola outbreak

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Congo approves Merck vaccine in face of Ebola outbreak

The Democratic Republic of the Congo approved the use of Merck & Co. Inc.'s experimental Ebola vaccine rVSV-ZEBOV to contain the virus' outbreak in the country, Reuters reported.

Although not licensed, Merck's vaccine was found to be highly protective against the deadly virus in a trial carried out on nearly 12,000 people in nearby Guinea in 2015.

The outbreak occurred in the northeast part of the country and has claimed four lives, with 52 suspected cases.